Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Breast Cancer Research and Treatment, 05/04/2012
Nahta R et al. – Emerging data suggests that crosstalk between these pathways is also involved in resistance to HER2–directed agents. Unraveling the role of the ER pathway in resistance to HER2–directed agents could potentially result in therapeutic approaches that can improve outcome for patients with ER–positive, HER2–positive breast cancer.
